SPHERA FUNDS MANAGEMENT LTD.

13F Filings History

Latest 13F report
Q3 2024 - Nov 14, 2024
Value $
$610M
Signature - Title
Oshrat Levi - Chief Financial Officer
Location
Tel Aviv, Israel
Summary
This page shows a list of all the recent 13F filings made by SPHERA FUNDS MANAGEMENT LTD.. Form 13F is required to be filed within 45 days of the end of a calendar quarter. SPHERA FUNDS MANAGEMENT LTD. reported 108 stock holdings with total value $610M as of Q3 2024. Top holdings included TEVA, SNY, BBIO, SNDX, and AMZN.
Holdings Value
Quarter Holdings Value $ Bought Sold Net Top Holdings Form Type Date Filed
Q3 2024 108 $610M +$137M -$136M +$886K TEVA, SNY, BBIO, SNDX, AMZN 13F-HR 11/14/2024, 03:15 PM
Q2 2024 110 $610M +$168M -$126M +$42.6M BBIO, SNY, CYTK, AMZN, SNDX 13F-HR 8/14/2024, 03:36 PM
Q1 2024 93 $617M +$179M -$175M +$4.35M TEVA, SNY, NICE, CYTK, SNDX 13F-HR 5/15/2024, 03:42 PM
Q4 2023 89 $533M +$155M -$214M -$58.3M TEVA, SNY, CYTK, NVMI, SNDX Restatement 2/15/2024, 07:40 AM
Q3 2023 75 $417M +$80.8M -$86.1M -$5.3M SNY, AZN, JNJ, MRK, AMZN 13F-HR 11/14/2023, 03:54 PM
Q2 2023 76 $467M +$102M -$121M -$18.4M SNY, AZN, JNJ, NICE, AMZN 13F-HR 8/14/2023, 03:45 PM
Q1 2023 75 $462M +$241M -$86.2M +$154M SNY, NICE, AZN, JNJ, TEVA 13F-HR 5/15/2023, 04:14 PM
Q4 2022 58 $318M +$51.5M -$359M -$308M AZN, SNY, JNJ, SNDX, MRK 13F-HR 2/14/2023, 03:36 PM
Q3 2022 65 $565M +$201M -$156M +$44.5M AZN, LLY, SNY, JNJ, MRK 13F-HR 11/14/2022, 04:20 PM
Q2 2022 50 $527M +$141M -$170M -$29.5M AZN, JNJ, LLY, SNY, ABBV 13F-HR 8/15/2022, 03:32 PM
Q1 2022 59 $597M +$151M -$361M -$210M AZN, JNJ, SNY, ABBV, PFE 13F-HR 5/16/2022, 03:34 PM
Q4 2021 85 $842M +$218M -$403M -$185M ABBV, AZN, SNY, LLY, MRK 13F-HR 2/14/2022, 03:24 PM
Q3 2021 107 $1.01B +$351M -$350M +$235K LLY, AZN, ABBV, PFE, SNY 13F-HR 11/15/2021, 03:41 PM
Q2 2021 121 $1.05B +$259M -$356M -$97.1M AZN, JNJ, MRK, SNY, GNRC 13F-HR 8/16/2021, 06:15 PM
Q1 2021 158 $1.09B +$463M -$305M +$158M LLY, JNJ, ABBV, MRK, SNY 13F-HR 5/17/2021, 06:01 AM
Q4 2020 104 $963M +$386M -$406M -$20.1M LLY, MRK, JNJ, NVS, BMY 13F-HR 2/16/2021, 06:29 AM
Q3 2020 89 $864M +$255M -$267M -$12.3M MRK, ABBV, JNJ, SNY, AZN 13F-HR 11/12/2020, 06:59 AM
Q2 2020 80 $840M +$344M -$211M +$132M ABBV, MRK, SNY, AZN, JNJ 13F-HR 8/13/2020, 06:02 AM
Q1 2020 75 $604M +$200M -$258M -$57.3M MRK, JNJ, BMY, SNY, NVO 13F-HR 5/14/2020, 07:49 AM
Q4 2019 81 $754M +$218M -$251M -$32.4M JNJ, BMY, SNY, MRK, NVO 13F-HR 2/13/2020, 12:11 PM
Q3 2019 79 $647M +$242M -$202M +$39.8M BMY, JNJ, GILD, MRK, SNY 13F-HR 11/14/2019, 06:01 AM
Q2 2019 84 $660M +$181M -$231M -$50.1M JNJ, ALXN, BMY, MRK, AZN 13F-HR 8/14/2019, 06:02 AM
Q1 2019 2 $0 $0 $0 New Holdings 6/20/2019, 07:37 AM
Q1 2019 98 $724M +$233M -$215M +$17.9M BMY, JNJ, FOLD, ALXN, MRK 13F-HR 5/15/2019, 06:23 AM
Q4 2018 98 $551M +$184M -$220M -$36.5M MYL, MRK, BMY, CELG, FOLD 13F-HR 2/14/2019, 06:42 AM
Q3 2018 111 $764M +$291M -$180M +$111M MRK, MYL, JNJ, GSK, BMY 13F-HR 11/14/2018, 12:39 PM
Q2 2018 107 $619M +$230M -$232M -$1.72M MRK, MYL, GSK, GILD, SHPG 13F-HR 8/13/2018, 08:30 AM
Q1 2018 104 $573M +$188M -$232M -$43.6M MRK, SHPG, CELG, FOLD, MYL 13F-HR 5/10/2018, 08:44 AM
Q4 2017 130 $618M +$201M -$132M +$69M CELG, MYL, MRK, BIIB, SRPT 13F-HR 2/12/2018, 02:44 PM
Q3 2017 121 $551M +$145M -$118M +$26.7M CELG, BIIB, MRK, GILD, GSK Restatement 11/27/2017, 10:57 AM
Q2 2017 119 $476M +$167M -$83.2M +$83.7M CELG, BIIB, MRK, GSK, GILD 13F-HR 8/9/2017, 10:08 AM
Q1 2017 104 $373M +$146M -$112M +$33.9M CELG, BIIB, NVS, MRK, SRPT 13F-HR 5/11/2017, 06:08 AM
Q4 2016 98 $321M +$80.3M -$180M -$99.9M MRK, CELG, TEVA, ALXN, CLCD 13F-HR 2/13/2017, 08:44 AM
Q3 2016 101 $434M +$137M -$74.7M +$61.9M MRK, TEVA, SRPT, AGN, LLY 13F-HR 11/14/2016, 07:46 AM
Q2 2016 83 $329M +$121M -$143M -$21.5M TEVA, AGN, GILD, LLY, CELG 13F-HR 8/10/2016, 10:17 AM
Q1 2016 82 $355M +$90.1M -$176M -$86.2M PFE, TEVA, BIIB, AGN, GILD 13F-HR 5/16/2016, 06:17 AM
Q4 2015 112 $510M +$138M -$168M -$29.8M TEVA, PFE, BIIB, AGN, ABBV 13F-HR 2/11/2016, 09:46 AM
Q3 2015 118 $499M +$152M -$202M -$50.1M AGN, TEVA, BIIB, PFE, ABBV 13F-HR 11/16/2015, 06:05 AM
Q2 2015 121 $644M +$230M -$295M -$65M AGN, GILD, PFE, ABBV, BIIB 13F-HR 8/6/2015, 01:19 PM
Q1 2015 136 $679M +$322M -$230M +$91.8M B108PS, PFE, GILD, TEVA, ABBV 13F-HR 5/11/2015, 06:43 AM
Q4 2014 117 $528M +$168M -$282M -$114M NVS, B108PS, PFE, TEVA, SLXP 13F-HR 2/12/2015, 12:42 PM
Q3 2014 117 $594M +$305M -$97.3M +$208M NVS, PFE, TEVA, B108PS, MRK Restatement 11/20/2014, 07:33 AM
Q2 2014 86 $369M +$145M -$167M -$22.5M NVS, MRK, TEVA, JNJ, PFE Restatement 8/20/2014, 06:03 AM
Q1 2014 99 $391M +$196M -$94.4M +$102M NVS, GSK, MRK, PFE, JNJ 13F-HR 5/14/2014, 12:02 PM
Q4 2013 87 $278M $0 $0 GSK, PFE, XLF, MRK, SHPG 13F-HR 2/13/2014, 02:03 PM